Subthalamic nucleus-deep brain stimulation improves autonomic dysfunctions in Parkinson’s disease

Feng Zhang1, Feng Wang2,3, Cong-Hui Li1, Ji-Wei Wang1, Chun-Lei Han4, Shi-Ying Fan5, Dong-Mei Gao4, Yu-Jing Xing1, Chen Yang1, Jian-Guo Zhang4 and Fan-Gang Meng4,5,6,7*

Abstract

Background: To study the effects of subthalamic nucleus-deep brain stimulation (STN-DBS) on autonomic dysfunctions in Parkinson’s disease (PD) patients.

Methods: A total of 57 PD patients who underwent bilateral STN-DBS from March to December 2018, were retrospectively analyzed. Preplanned assessments at baseline and postoperatively at 1, 3, and 6 months also included the Scales for Outcomes in Parkinson’s Disease-Autonomic questionnaire (SCOPA-Aut), the Unified Parkinson’s Disease Rating Scale (UPDRS) III score, levodopa equivalent day dose (LEDD), Parkinson’s Disease Quality of Life Scale (PDQ-39), the Hamilton Anxiety Rating Scale (HAMA), and the Hamilton Depression Rating Scale (HAMD).

Results: The SCOPA-Aut scores improved significantly [14.59% (18.32%), 24.00% (27.05%), 22.16% (27.07%), all P < 0.001] at 1 month, 3 months, and 6 months of STN-DBS, respectively. Analysis of the SCOPA-Aut sub-items showed significant improvements only in urine and thermoregulation sub-items at 6 months after surgery (P < 0.001). There was no significant correlation between improvements of SCOPA-Aut scores and improvements of PDQ-39 scores (P > 0.05) at 6 months after surgery. SCOPA-Aut scores were positively correlated with age (r = 0.428, P = 0.001); the improvements of SCCOPA-Aut scores were positively correlated with improvements of HAMA and HAMD scores (HAMA: r = 0.325, P = 0.015; HAMD: r = 0.265, P = 0.049) at 6 months after surgery.

Conclusion: STN-DBS improved autonomic dysfunction symptoms of PD patients, and urinary and thermoregulatory sub-items of autonomic dysfunction were improved in the short-term after surgery. There was a close relationship between improved autonomic symptoms and improved anxiety and depression 6 months after surgery. We should therefore direct more attention to autonomic dysfunctions in PD involving detailed preoperative evaluations and postoperative follow-ups, to improve the quality of life of patients.

Keywords: Parkinson’s disease, Deep brain stimulation, Subthalamic nucleus, Autonomic dysfunction, Non-motor symptoms

*Correspondence: fgmeng@ccmu.edu.cn
4 Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
Full list of author information is available at the end of the article
(NMS) have been less reported. NMS may have a greater impact on QOL than motor symptoms. Dysfunctions of the autonomic nervous system (gastrointestinal symptoms, urinary symptoms, cardiovascular symptoms, thermoregulation, pupillomotor functions, and sexual functions) are common in PD, and autonomic dysfunctions may appear earlier than major motor symptoms of PD, and significantly impair the QOL. Autonomic dysfunctions are associated with the accumulation of Lewy bodies in the nervous system, and the peripheral autonomic nervous system may be a key route for α-synuclein pathology propagation from the periphery to the central nervous system. PD progression and dopaminergic drug therapy may also aggravate autonomic dysfunctions. The effects of STN-DBS on autonomic symptoms such as sweating, urgency, increased frequency or incontinence, have not been well studied. The loss of central dopamine leads to motor symptoms, which can also lead to autonomic dysfunctions. Thus, we speculated that STN-DBS may improve autonomic dysfunctions. In the present study, we evaluated the effects of bilateral STN-DBS on autonomic dysfunctions during 6 months of chronic stimulation, and determined their relationships with motor symptoms, anxiety, depression, and the QOL.

Materials and methods
Between March and December 2018, a total of 57 patients were hospitalized at the Department of Neurosurgery of the Beijing Tiantan Hospital Affiliated to Capital Medical University, the First Hospital of Hebei Medical University, and the General Hospital of Ningxia Medical University to optimize a previously-performed STN-DBS, as previously reported [5].

The study was approved by the Medical Ethics Committee of the First Hospital of Hebei Medical University and the Medical Ethics Committee of Beijing Tiantan Hospital Affiliated to Capital Medical University. The ethical principles involved in this research were in accordance with the Declaration of Helsinki, and all patients provided written informed consent, as mentioned in our previous report [5].

Patient selection
Evaluations were conducted by neurologists specializing in movement disorders. Patients with advanced idiopathic PD were diagnosed based on the diagnostic criteria for PD in China (2016 edition), and PD surgical treatment evaluation criteria [6, 7]. None of the patients had serious cognitive impairments or mental illness. All patients underwent preoperative testing and were analyzed by the levodopa challenge test, confirming that the levodopa response needed to be improved by at least 30%. Those individuals who had complete imaging and scoring data were followed-up on a regular basis. Morphological magnetic resonance imaging was performed to exclude patients with severe cerebral atrophy and ischemic disease.

Clinical evaluation
Demographic characteristics (age, sex, age at onset, and duration of the disease) and disease severity were assessed by the Unified Parkinson’s Disease Rating Scale (UPDRS)-III scores (range: 0 – 132). The Hoehn-Yahr scale (0 – 5) was used for disease staging. The therapeutic medical regimen was recorded, which calculated the levodopa equivalent dose (LEDD) according to Tomlinson et al. [8]. As part of the preplanned investigations performed at baseline, and after 1, 3, and 6 months of STN-DBS, autonomic symptoms were assessed with the Scopa-Aut questionnaire (0 – 69) [9], consisting of 26 items. It included gastrointestinal symptoms (seven items), urinary symptoms (six items), cardiovascular symptoms (three items), thermoregulation (four items), pupillomotor function (one item), sexual function (two separate items for each sex) [9]. Each item was scored from 0 (never) to 3 (often), except for question 26, which was a yes/no question, and consequently not included in our statistical analysis. SCOPA-Aut scores ranged from 0 to 69, with higher scores expressing more severe symptoms. Anxiety and depression outcomes were assessed using the Hamilton Anxiety Rating Scale (HAMA) (14 parts). The HAMA ranged from 0 to 56 and the Hamilton Depression Rating Scale (HAM-D) (24 parts) ranged from 0 to 68. The quality of life (QOL) was assessed using the 39-item Parkinson’s Disease Questionnaire (PDQ-39), ranging from 0 to 124. Postoperative improvement (%) was calculated as the preoperative score—postoperative score/preoperative score × 100%. Clinical assessments were performed at preoperative baseline (Med-OFF and Med-ON), 1 month after surgery (follow-up 1), 3 months after surgery (follow-up 2), and 6 months after surgery (follow-up 3).

Surgical procedures
Surgical procedures were conducted as previously described [5].

Stimulation programming
One month after surgery, we turned on the stimulator and programmed the IPG [10], tested the contacts on each electrode, and selected the best stimulation target when the patient obtained satisfactory improvement with minimal side effects. Then, if necessary, the parameters were adjusted using the remote program control. We first used the unipolar stimulation mode, with the following stimulation parameters: the voltage was 1.5 ~ 2.0 V, the
frequency was 130 Hz, and the pulse width was 60 ms. We then gradually adjusted the stimulation parameters until the best therapeutic effect was achieved.

Statistical analyses
All statistical analyses were performed using SPSS statistical software for Windows, version 25.0 (SPSS, Chicago, IL, USA). Continuous variables that followed, or approximately followed, a normal distribution are presented as the mean ± standard deviation (x±s). Continuous variables that did not follow a normal distribution and the Kruskal–Wallis rank sum test was used for comparisons between multiple groups. The correlation analysis method was used to identify factors influencing the improvement of autonomic dysfunctions after DBS. The statistical significance threshold was fixed at P<0.05.

Results
Patient population
As previously reported [5], the study group was comprised of 34 males and 23 females. The LEDD of the 57 preoperative patients was (866.3±357.0) (125–1625) mg/d, and the preoperative Hoehn-Yahr stage was (2.9±0.3) (2 − 4).

Clinical outcomes
In this study, 57 patients were included, operated, and examined preoperatively, with planned follow-ups after 1, 3, and 6 months of continuous STN-DBS. Comparisons between preoperative and postoperative (1, 3, and 6 months after surgery) clinical stages are summarized in Table 1 and Fig. 1. At 6 months of follow-up, the SCOPA-Aut scores (scales for outcomes in PD autonomic symptoms) [M (IQR)] improved significantly [14.59% (18.32%), 24.00% (27.05%), 22.16% (27.07%), respectively, all P<0.001] at 1, 3, and 6 months of STN-DBS, respectively. Analysis of the SCOPA-Aut sub-items showed significant improvements only in the urine [36.93% (60.00%)] and thermoregulation [40.00% (66.67%)] sub-items at 6 months after surgery (P<0.001).

As previously reported [5], UPDRS-III scores (medication-OFF) improved (55.42%), the PDQ-39 scores improved (47.39%), and the LEDD decreased by 40.08% at 6 months after surgery. The improvements of HAMA scores and HAMD scores of 57 patients were [41.7(34.9)% and 37.5(33.4)%, respectively (both, P<0.001)].

The correlation analyses
1. There were correlations between the improvements of SCOPA-Aut scores, LEDD, and PDQ-39 scores, and the improvements of UPDRS-III scores (Med-OFF) (Table 2). There was no significant correlation between the improvement of SCOPA-Aut scores and the improvement of UPDRS-III scores (Med-OFF) (P>0.05).
2. There was a correlation between the improvement of SCOPA-Aut scores and the improvement of PDQ-39 scores (Table 2). There was no significant correlation between the improvement of SCOPA-Aut scores and the improvement of PDQ-39 scores (all, P>0.05) (Table 3).
3. There was a correlation between the improvement of SCOPA-Aut scores and the improvements of

Table 1 Comparison of preoperative and postoperative clinical state [M (IQR)]

| Time          | Preoperative | Postoperative | Total P | χ2    | P1   | P2   | P3   |
|---------------|--------------|---------------|---------|-------|------|------|------|
|               | 1 month      | 3 month       | 6 month |
| SCOPA-Aut     |              |               |         |       |      |      |      |
| SCOPA-Aut (0–69) total | 22 (12) | 18 (14) | 18 (10) | 16 (12) | 0.003 | 5.399 | 0.001 | 0.001 | < 0.001 |
| Gastrointestinal (Q1–7) | 4 (2.8) | 4 (4) | 4 (2.8) | 4 (2) | 0.107 | 2.133 | 0.062 | 0.193 | 0.065 |
| Urinary (Q8–13) | 7 (4) | 4.5 (3.8) | 4 (5) | 4 (5) | < 0.001 | 11.062 | < 0.001 | < 0.001 | < 0.001 |
| Cardiovascular (Q14–16) | 2 (1.8) | 2 (1) | 2 (1.7) | 2 (2) | 0.248 | 1.418 | 0.049 | 0.107 | 0.345 |
| Thermoregulatory (Q17–21) | 4 (2) | 3 (2.8) | 3 (3) | 3 (2.8) | < 0.001 | 8.049 | < 0.001 | < 0.001 | < 0.001 |
| Pupillomotor (Q19) | 1 (2) | 1 (2) | 1 (2) | 1 (2) | 0.264 | 1.362 | 0.159 | 0.073 | 0.088 |
| Sexual (Q22–25) | 2 (1.7) | 2 (2) | 2 (1) | 2 (1.7) | 0.792 | 0.346 | 0.659 | 0.871 | 0.542 |
| HAMA (0–56) | 16 (14) | 11 (11) | 9 (10) | 11 (11) | < 0.001 | 12.839 | < 0.001 | < 0.001 | < 0.001 |
| HAMD (0–68) | 14 (13) | 9 (9) | 9 (8) | 9 (9) | < 0.001 | 11.664 | 0.044 | < 0.001 | < 0.001 |

P1, P2 and P3 values are, respectively, the results of comparisons between preoperative results and results 1, 3 and 6 months after surgery, SCOPA-Aut the Scale for Outcomes in PD for Autonomic Symptoms, HAMA Hamilton Anxiety Rating Scale, HAMD Hamilton Depression Rating Scale
Fig. 1 SCOPA-Aut and LEDD comparison between pre- and postoperative clinical state. **A-B** SCOPA-Aut scores were improved by 22.16% 6 months after surgery; **C-D** the reduction rate of LEDD was 40.08% at 6 months after surgery (**P < 0.001**). (STN-DBS: subthalamic nucleus—deep brain stimulation; SCOPA-Aut: the Scale for Outcomes in PD for Autonomic Symptoms; LEDD: Levodopa equivalent dose) [Baseline: baseline; FU1: 1 month after surgery; FU2: 3 months after surgery; FU3: 6 months after surgery]

Table 2 The correlation between the improvement rate of SCOPA-Aut scores, and clinical parameters 6 months after surgery

| Parameter       | Improvement rate (%) | SCOPA-Aut improvement rate (%) | r    | P     |
|-----------------|----------------------|--------------------------------|------|-------|
| UPDRS-III (Med-off) | 55.42                | 22.16                          | 0.086| 0.527 |
| PDQ-39          | 47.39                | 22.16                          | 0.126| 0.355 |
| HAMA            | 34.27                | 22.16                          | 0.352| 0.015 |
| HAMD            | 26.95                | 22.16                          | 0.265| 0.049 |
HAMA, and HAMD scores (Table 2). The improvement of SCOPA-Aut scores was positively correlated with the improvement of HAMA scores ($r=0.325$, $P=0.015$). The improvement of SCOPA-Aut scores was positively correlated with the improvement of HAMD scores ($r=0.265$, $P=0.049$), indicating that the better the improvement of anxiety and depression, the better the improvement of autonomic dysfunctions.

4. There were correlations of SCOPA-Aut scores, PDQ-39 scores, and clinical variables (Table 4). For SCOPA-Aut scores, there was no correlation with disease duration and Hoehn-Yahr grade ($P>0.05$), but there was a positive correlation with age ($r=0.428$, $P=0.001$), indicating that the older the PD patients, the more serious the autonomic dysfunction symptoms. For PDQ-39 scores, there were positive correlations with disease duration ($r=0.296$, $P=0.025$) and Hoehn-Yahr grade ($r=0.366$, $P=0.005$).

Discussion

DBS is widely used in the clinical treatment of PD because it is minimally invasive, adjustable, and reversible. Most PD patients experience autonomic dysfunctions at different clinical stages, with an incidence of 14%–80% [11, 12]. Autonomic dysfunctions of PD patients include gastrointestinal malfunction (constipation, dysphagia, or choking); urinary disturbance (increased nocturia, frequent urination, and endless urination); sexual dysfunction (impotence, vaginal dryness, etc.); thermoregulatory aberrance (sweat, intolerance, etc.); cardiovascular dysregulation (postural hypotension and dizziness), and pupillo-motor and tear abnormalities [13], which seriously affect the QOL of PD patients. In this retrospective study of 57 PD patients treated with STN-DBS, using correlation analysis, it was found that the older the PD patient, the more serious the autonomic dysfunction. It was speculated that the older age of onset of Lewy bodies was related to the deposition of parts related to autonomic dysfunctions.

The mechanism for the improvement of symptoms of autonomic dysfunctions may be that STN-DBS directly regulates the basal ganglia-thalamus-cortical circuit, thereby regulating the thalamus, lateral frontal lobe, and anterior cingulate gyrus (the center of the autonomic nervous system) to improve the symptoms of autonomic dysfunctions [14]. The effect of STN-DBS on gastrointestinal dysfunction involves reducing constipation, dysphagia, and salivation [15]. Studies have shown that the effects of STN-DBS on urinary disturbance involved reducing detrusor muscle tension, and increasing bladder capacity and reflexing volume [16]. The severity of bladder dysfunction seems to be associated with relative degeneration of the caudate nucleus, among other areas [17]. STN-DBS can improve the temperature perception of PD patients, and DBS can improve hyperhidrosis and heat intolerance [18], which may be related to stimulation of the tail of STN, the ventral thalamus, and the zona incerta (ZI). The effect of STN-DBS on sexual dysfunction may be related to stimulations of the medial preoptic nucleus, anterior hypothalamic nucleus, and nucleus accumbens, resulting in changes in their activities [19]. The effect of STN-DBS on cardiovascular dysfunction involves increasing heart rate, and the sensitivity of baroreceptors and peripheral vascular tone, which can improve postural hypotension in PD patients [20], and which may be related to stimulating the limbic of STN or the ZI [21]. Frontal cortex, cingulate cortex, insula, thalami, basal ganglia, and periaqueductal grey matter may be related to gastrointestinal functions [22]. STN-DBS can activate the nerve fibers projecting from hypothalamus and crossing the subthalamic nucleus, that might be affecting gastrointestinal functions. Previous studies have shown that STN-DBS could improve autonomic dysfunctions in PD patients [23–27]. Few previous reports have used SCOPA-Aut to assess the effects of STN-DBS on autonomic dysfunctions. Previous studies have used

| Table 3 The correlation between the improvement rate of Urinary; Thermoregulat scores and the improvement rate of PDQ-39 scores 6 months after surgery |
|---------------------------------|----------------|--------|
|                                 | improvement rate (%) | the improvement rate of PDQ-39 scores (%) | $r$ | $P$ |
| Urinary                        | 36.93            | 47.39  | 0.013 | 0.926 |
| Thermoregulat                  | 40.00            | 47.39  | 0.022 | 0.875 |

| Table 4 The correlation between SCOPA-Aut scores, PDQ-39 scores and clinical variables 6 months after surgery |
|-----------------|-----------------|--------|-----------------|-----------------|--------|
|                 | Age             | Disease duration | Hoehn-Yahr grade |
|                 | $r$             | $P$           | $r$             | $P$           |
| SCOPA-Aut       | 0.428           | 0.001         | 0.221           | 0.101         |
| PDQ-39          | 0.006           | 0.967         | 0.296           | 0.025         |
|                 |                 |               | 0.366           | 0.005         |
NMSQ to assess NMS [28]. However, this scale is only for NMSS, and not specifically for autonomic dysfunctions. The improvement of dysautonomic fluctuations after chronic stimulation was remarkable, especially for some symptoms. Urine showed the greatest reduction in the number of symptoms reported by patients after surgery. Regarding autonomic symptoms, the significant improvement of Scopa-Aut total scores after 6 months of STN-DBS, with the SCOPA-Aut total score increased by 22.16% ($P < 0.001$) after 6 months of follow-up, indicating that STN-DBS improved autonomic dysfunctions of PD patients in the short term. However, the results were not equal for all categories of symptoms. Analyses of each SCOPA-Aut domain showed significant improvements at 6 months only for the urinary and thermoregulatory dysfunctions, which showed a remarkable decrease after chronic stimulation. A study of 24 patients reported similar results, with Scopa-Aut improving after 3 months of follow-up, but with subsequent deterioration [29]. Further follow-up studies are necessary to confirm these results. A prospective study with preoperative and postoperative urodynamics would provide more detailed information about the effects of STN-DBS on bladder function. We could not predict the preoperative impact on SCOPA-Aut, but the parallel improvement of PDQ-39 scores were identified as a significant co-variate. This might imply that the degree of improvement of autonomic dysfunction played an important role in improving the QOL. However, there was no significant correlation between the improvement of SCOPA-Aut scores and the improvement of PDQ-39 scores ($P > 0.05$). Furthermore, there was no significant correlation between the improvement of urinary and thermoregulatory scores, and the improvement of PDQ-39 scores (all, $P > 0.05$), which may have been due to many factors involving the STN-DBS effects on the QOL, in addition to motor symptoms associated with other important roles. The NMS impact was also very important, not just the autonomic dysfunctions, such as anxiety, depression, numbness, pain, sleep disorders, cognitive impairment, hallucinations, and other influences, which were significant, so we need to consider many factors, and judge them comprehensively.

In the present study, there were negative results of cardiovascular, gastrointestinal, and sexual functions of autonomic dysfunctions after STN-DBS. It may be because STN-DBS had no direct effect on autonomic cardiac innervation or muscle vasoconstrictor neurons [30]. Gastrointestinal function depends not only on central but also peripheral autonomic structures, which might not be systems modulated by STN-DBS [31]. DBS-STN has no direct effect on the PD patients’ sexual life. Emotional well-being may contribute to a different opinion of the sexual function according to the patient’s sex [32].

In previous reports, SCOPA-Aut scores increased by age and disease duration [33]. In our study, SCOPA-Aut total scores increased by age, indicating that the autonomic dysfunction gradually worsened with age.

Autonomic dysfunction is related to emotional disorders, and may involve a common mechanism [34]. The 5-HT neurotransmitter system in patients with PD may be one of the mechanisms related to autonomic dysfunctions and emotional disorders. In our study, the improvement of SCOPA-Aut scores was positively correlated with the improvement of HAMA scores ($r = 0.325$, $P = 0.015$). The improvement of SCOPA-Aut scores was positively correlated with the improvement of HAMD scores ($r = 0.265$, $P = 0.049$), indicating that with improvements of anxiety and depression symptoms in PD disease, autonomic dysfunction would also improve.

The QOL dysfunctions deserve more focus, both in the preoperative and postoperative evaluations of PD patients for STN-DBS. Future studies should consider including these factors among the main outcomes, especially in studies focusing on optimal electrode location and tissue activation in STN, closed-loop DBS, directional electrodes, functional brain imaging, and brain networks.

**Limitations**

There were some limitations in this study. (1) The sample was small and it was a retrospective study. (2) SCOPA-Aut scores for preoperative evaluation of autonomic dysfunctions were subjective. (3) The postoperative follow-up time was 6 months, which was short. (4) A large number of statistical tests were conducted without performing corrections for multiple testing.

**Conclusion**

STN-DBS improved autonomic dysfunctions of PD, urinary, and thermoregulatory aspects of autonomic dysfunctions, which were postoperatively improved in the short term. There was a close relationship between improved autonomic dysfunctions and improved anxiety and depression at 6 months. We should therefore direct more attention to autonomic dysfunctions in PD patients, involving detailed preoperative evaluations and postoperative follow-ups, to improve the QOL of patients.

**Abbreviations**

PD: Parkinson’s disease; STN: Subthalamic nucleus; DBS: Deep brain stimulation; UPDRS-III: Unified Parkinson’s Disease Rating Scale-Part III; LEDD: Levodopa equivalent day dose; QOL: Quality of life; PDQ-39: 39-Item Parkinson’s Disease Questionnaire; NMS: Non-motor symptom; SCOPA-Aut: The Scales for Outcomes in Parkinson’s Disease-Autonomic questionnaire; HAMA: The Hamilton Anxiety Rating Scale; HAMD: The Hamilton Depression Rating Scale;
LCT: Levodopa challenge test; Med-off: Medication-off; Med-on: Medication-on; IPG: Implantable pulse generator.

Acknowledgements
We are grateful to all the patients recruited for this study. We thank the Medical Ethics Committee of the First Hospital of Hebei Medical University and the medical ethics committee of IRB of Beijing Tiantan Hospital Affiliated to Capital Medical University for the approval of our study.

Authors’ contributions
Study concept and design: F. Z, FG M. Data collection: F. Z, SY F, CL H, DM G, CH L, JW W, YI X, C. Y. Analysis and interpretation: F. Z, F W, CH L, JW W. Drafting of the manuscript: F. Z. Critical revision of the manuscript: F. Z, FG M. Study supervision: F. Z, FG M. F. Z was a major contributor in writing the manuscript. The authors read and approved the manuscript.

Funding
This study was funded by S&T Program of Hebei(21377736D), Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (XMLZ201833, ZYLLX201820), National Natural Science Foundation of China (81971070). The funder had no role in the study design, data collection, or analysis, the decision to publish or the preparation of the manuscript.

Availability of data and materials
The datasets used and/or analyzed during the current study not publicly available due to privacy reasons of patients, but are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
All authors clearly consented to and approved this manuscript. The study strictly followed the ethical principles set out in the “Declaration of Helsinki.” All patients and their families (spouse or children) have informed consent and signed an informed consent form, the study was approved by the Medical Ethics Committee of the First Hospital of Hebei Medical University and the Medical Ethics Committee of Beijing Tiantan Hospital affiliated to Capital Medical University, and the ethics committee approved this form of proxy consent. All authors clearly consented to and approved this manuscript. The study

criteria for Parkinson's disease in China (2016 edition) [J]. Chin J Neurol. 2021;21(1):122. https://doi.org/10.1186/s12883-021-02148-1.

Zhang F, Wang F, Li W, et al. Relationship between electrode position of deep brain stimulation and motor symptoms of Parkinson's disease. BMC Neurol. 2021;21(1):22. https://10.1186/s12883-021-02148-1.

6. Parkinson’s Disease and Dyskinesia Group, Neurology Branch, Chinese Medical Association, Professional Committee of Parkinson’s Disease and Dyskinesia, Neurologist Branch. Chinese Medical Association. Diagnostic criteria for Parkinson’s disease in China (2016 edition) [J]. Chin J Neurol. 2016;49(4):268–71. https://doi.org/10.3763/cma.jsa.1006-7876.201604.002.

7. Zach H, Walter U, Liepelt-Scarfone I, et al. Diagnostics of clinical and prodromal idiopathic Parkinson’s disease: New criteria. Nervenarzt. 2017;88(Suppl 6):56–64. https://doi.org/10.1007/s00115-017-0290-6.

8. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–53. https://doi.org/10.1002/mds.23429.

Visser M, Marinus J, Stiggelbout AM, et al. Assessment of autonomic dysfunction in Parkinson’s disease: the Scopa-Aut. Mov Disord. 2004;19(1):1026–31. https://doi.org/10.1002/mds.1553.

9. Horn A, Reich M, Vorwerk J, et al. Connectivity Predicts deep brain stimulation outcome in Parkinson disease. Ann Neurol. 2017;82(1):67–78. https://doi.org/10.1002/ana.24974.

10. Sjoødal HC, Høgell P, Nilsson MH. Motor and non-motor predictors of illness-related distress in Parkinson’s disease [J]. Parkinsonism Relat Disord. 2012;18(3):299–302. https://doi.org/10.1016/j.parkreldis.2011.10.002.

11. Martinez-Martín P, Valdeireoia F, Tolosa E, et al. Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson’s disease. Mov Disord. 2001;2002(17):372–7. https://doi.org/10.1002/mds.10044.

12. Zhang Z, Chen SD. Research progress of autonomic dysfunction in Parkinson’s disease. Chin J Contemp Neurol Neurosurg. 2019;19(5):367–73. https://doi.org/10.3969/j.issn.1672-6731.201905.012.

13. Trachani E, Constantoyannis C, Siriou V, et al. Effects of subthalamic nucleus deep brain stimulation on sweating function in Parkinson’s disease. Clin Neurother. 2011;12(3):213–7. https://doi.org/10.1016/j.clinther.2009.11.015.

14. Lengerer S, Kipping J, Rommel N, et al. Deep-brain-stimulation does not impair deglutition in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(7):847–53. https://doi.org/10.1016/j.parkreldis.2012.04.014.

15. Herzog J, Weiss PH, Assmann A, et al. Improved sensory gating of urinary bladder afferents in Parkinson’s disease following subthalamic stimulation. Brain. 2008;131:132–45. https://doi.org/10.1093/brain/aws254.

16. Fowler CJ, Dalton C, Panicker JN. Review of neurologic diseases for the urologist. Urol Clin North Am. 2010;37(4):517–26. https://doi.org/10.1016/j.ucl.2010.07.004.

17. Witjas T, Kaphan E, Regis J, et al. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson’s disease. Mov Disord. 2007;22:1729–34. https://doi.org/10.1002/mds.21602.

18. Wang XH, Zhang L, Wang SJ, et al. Effects of deep brain stimulation on non-motor symptoms of Parkinson’s disease. J Clin Neurol. 2011;8(3):147–50.

19. Liu KD, Shan DE, Kuo TB, et al. The effects of bilateral stimulation of the globus pallidus in patients with Parkinson’s disease. J Neurol. 2013;260(7):1714–23. https://doi.org/10.1007/s00415-013-6849-7.

20. Priori A, Cinnante C, Genitrini S, et al. Non-motor effects of deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: preliminary physiological results. Neurol Sci. 2001;22(1):85–6. https://doi.org/10.1007/s10072-001-70059.

21. Vandenbergh J, Duport P, Fischer B, et al. Regional brain activation during proximal stomach distention in humans: A positron emission tomography study. Gastroenterology. 2005;128(3):564–73. https://doi.org/10.1053/j.gastro.2004.11.054.

22. Halim A, Baumgartner L, Binder DK. Effect of deep brain stimulation on autonomic dysfunction in patients with Parkinson’s disease. J Clin Neurosci. 2011;18:804–6. https://doi.org/10.1016/j.jocn.2010.10.015.

References
1. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386:896–912. https://doi.org/10.1016/S0140-6736(14)61393-3.
2. Wichmann T, Delong MR. Deep brain stimulation for movement disorders of basal ganlia origin: restoring function or functionality? [J]. Neurotherapeutics. 2016;13:264–83. https://doi.org/10.1007/s13311-016-0426-6.
24. Herzog J, Weiss PH, Assmuss A, et al. Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson’s disease. Brain. 2006;129:3366–75. https://doi.org/10.1093/brain/awl302 (Epub 2006 Oct 31).

25. Trachani E, Constantoyannis C, Sirrou V, et al. Effects of subthalamic nucleus stimulation on sweating function in Parkinson’s disease. Clin Neurol Neurosurg. 2012;112:213–7. https://doi.org/10.1016/j.clineuro.2009.11.015 (Epub 2009 Dec 22).

26. Nazzaro JM, Pahwa R, Lyons KE. The impact of bilateral subthalamic stimulation on non-motor symptoms of Parkinson’s disease. Parkinsonism Rel Disord. 2011;17:606–9. https://doi.org/10.1016/j.parkreldis.2011.05.009 (Epub 2011 Jun 12).

27. Arai E, Arai M, Uchiyama T, et al. Subthalamic deep brain stimulation can improve gastric emptying in Parkinson’s disease. Brain. 2012;135:1478–85. https://doi.org/10.1093/brain/aws086 (Epub 2012 Apr 19).

28. Chaudhuri KR, Martinez-Martín P, Anthony HV, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord. 2006;21(7):916–23. https://doi.org/10.1002/mds.20844.

29. Kurcova S, Bardon J, Vastik M, et al. Bilateral subthalamic deep brain stimulation initial impact on nonmotor and motor symptoms in Parkinson’s disease: an open prospective single institution study. Medicine (Baltimore). 2018;97(5):e9750. https://doi.org/10.1097/MD.00000000000009750.

30. Ludwig J, Remien P, Guballa C, et al. Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(7):742–5. https://doi.org/10.1136/jnnp.2006.105739.

31. Krygowska-Wajs A, Furgala A, Gorecka-Mazur A, et al. The effect of subthalamic deep brain stimulation on gastric motility in Parkinson’s disease. Parkinsonism Relat Disord. 2016;26:35–40. https://doi.org/10.1016/j.parkreldis.2016.02.010.

32. Pedro T, Sousa M, Rito M, et al. The Impact of Deep Brain Stimulation on the Sexual Function of Patients With Parkinson’s Disease. Neurologist. 2020;25(3):55–61. https://doi.org/10.1097/NRL.0000000000000272.

33. Arrnao V, Cintunno A, Valentinio F, et al. In patient's with Parkinson disease, autonomic symptoms are frequent and associated with other non-motor symptoms. Clin Auton Res. 2015;25(5):301–7. https://doi.org/10.1007/s10286-015-0306-x (Epub 2015 Sep 10).

34. Cao CJ, Yu SY, Zuo LJ, et al. Study on the correlation of autonomic dysfunction with motor symptoms and non-motor symptoms in patients with Parkinson’s disease. Chin J Clinicians (Electronic Edition). 2013;7(15):6896–903. https://doi.org/10.3877/cma.j.issn.1674-0785.2013.15.028.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.